Full for Hours on Ozempic or Mounjaro? That Feeling Is the Drug Working, and Your Procedure Team Needs to Know

Key Takeaways

• In a prospective ultrasound study of 220 surgical patients who had fasted by standard rules, 40 percent of those who had taken semaglutide within the previous 10 days still had food or excess fluid in the stomach, compared with 3 percent of those not taking it.
• In a 20-week randomized trial, people on semaglutide 2.4 mg ate 35 percent less at an all-you-want lunch and reported more fullness and less hunger, showing that much of the appetite effect works through the brain, not only the stomach.
• Retained stomach contents are found more often during endoscopy in people taking GLP-1 drugs, but they rarely lead to aspiration, and the evidence on how long to hold these medicines before a procedure is still limited.

If you take semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) and find yourself full after half a plate, still feeling lunch at four in the afternoon, you are not imagining it and nothing has gone wrong. That fullness is a large part of how these medicines work. Most people file it, along with the queasiness, under side effects, something to put up with until it fades. The part almost nobody mentions is what that same fullness means on the morning of a colonoscopy, an upper endoscopy or a surgery. You can follow the fasting instructions perfectly, nothing after midnight, and still arrive with food sitting in your stomach. That is the reason Ozempic and anesthesia has become a routine conversation in procedure suites, and the reason anesthesia teams now ask about these drugs by name. Under sedation the reflexes that normally protect your airway relax, and a stomach that is supposed to be empty but is not raises the theoretical risk of stomach contents traveling where they should not. The risk is small, but it is real enough that the people putting you to sleep want to know.

These drugs copy GLP-1, a hormone your own gut releases after meals. They act on appetite centers in the brain and also slow how quickly the stomach and small intestine move food along, which helps flatten the blood sugar rise after eating. The brain side is powerful on its own. In a 20-week randomized trial, adults on semaglutide 2.4 mg ate 35 percent less at an all-you-want lunch and reported more fullness and less hunger than those on placebo, yet an indirect test of stomach emptying showed no meaningful delay by week 20. The body partly adapts to the slowing over time. Solid food is another story. In a prospective study of 220 people fasting by standard rules before elective surgery, an ultrasound found food or excess fluid in the stomach of 40 percent of those who had taken semaglutide within 10 days, versus 3 percent of those who had not. An earlier endoscopy review found the same pattern, 24 percent versus 5 percent, and the number of days people had paused the drug beforehand was about the same whether or not food was left over. The reassuring part is that actual aspiration was rare in these studies.

Ozempic and anesthesia: do I need to stop it before a procedure?

I am less worried about the nausea than about people not telling the procedure team they are on it. A once-weekly injection is easy to leave off a medication list, especially when another doctor prescribed it or you think of it as a weight-loss shot rather than a medicine. Before any sedation, I would say it out loud twice: when the procedure is scheduled, and again to the anesthesia team that morning. Do not stop it on your own, particularly if you have diabetes, because blood sugars can climb quickly. In 2024 several anesthesia, gastroenterology and surgical societies issued joint guidance that moved away from one blanket rule toward judging each person's risk. Most people can keep taking the drug with the usual fasting. People at higher risk, such as those still increasing their dose or having nausea or bloating, may be asked to switch to liquids for the full day before, and only some are asked to skip a dose. Let the team that knows your situation decide. For everyday comfort, smaller meals, eating slowly, stopping at the first sign of fullness and going easy on greasy food usually help. Vomiting that will not stop, being unable to keep fluids down, severe belly pain that bores through to your back, or pain under the right ribs with fever deserve a call the same day. Your stomach may still be working on breakfast at dinnertime. Make sure the person putting you to sleep knows why.

References

1. Nersessian, R. S. F., da Silva, L. M., Carvalho, M. A. S., Silveira, S. Q., Abib, A. C. V., Bellicieri, F. N., et al. (2024). Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: A prospective observational study. Anaesthesia, 79(12), 1317-1324.
2. Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021). The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism, 23(3), 754-762.
3. Silveira, S. Q., da Silva, L. M., de Campos Vieira Abib, A., de Moura, D. T. H., de Moura, E. G. H., Santos, L. B., et al. (2023). Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. Journal of Clinical Anesthesia, 87, 111091.
4. Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., et al. (2024). Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. Journal of Clinical Endocrinology and Metabolism, 110(1), 1-15.
5. Kindel, T. L., Wang, A. Y., Wadhwa, A., Schulman, A. R., Sharaiha, R. Z., Kroh, M., et al. (2024). Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surgery for Obesity and Related Diseases, 20(12), 1183-1186.